← All trials
NCT05787600
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 3, 2023
- Primary completion
- Apr 20, 2023
- Completion date
- May 1, 2023
- First posted
- Mar 28, 2023
- Last posted
- Oct 4, 2023
- Enrollment
- 54
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BaghdadLead sponsor
- University of BaghdadOverall official - principal investigator
- University of BaghdadReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.